Formulary
When prescribing inhalers the drug, device (e.g. MDI, Easibreathe, Autohaler, Accuhaler), strength (micrograms per inhalation), number of puffs per dose and frequency MUST be specified
| Benralizumab Fasenra® |
|
Formulary
|
(Fasenra®) Solution for injection pre-filled syringes 30mg/1ml and solution for injection pre-filled pen 30mg /1ml Severe eosinophilic asthma in adults (add-on therapy) - NICE TA565
|
 NICE TA565: Benralizumab for treating severe eosinophilic asthma |
|
| Mepolizumab |
|
Formulary
|
(Nucala®) solution for injection pre-filled syringe 40mg / 0.4ml, 100mg powder for solution for injection, solution for injection pre-filled pen 100mg / 1ml, solution for injection in pre-filled syringe 100mg / 1ml Severe eosinophilic asthma in adults - NICE TA671 |
|
NICE TA671: Mepolizumab for treating severe eosinophilic asthma |
|
|
| Palforzia |
|
Formulary
|
Oral powder in capsules for opening 0.5mg, 1mg, 10mg, 20mg, 100mg, 300mg peanut protein as defatted powder of Arachis hypogaea L., semen (peanuts) In view of concerns about the safety of desensitising vaccines, it is recommended that they are used by specialists and only for licensed indications. Self-injectable adrenaline must be prescribed to patients receiving this medicinal product. |
|
NICE TA769: Palforzia for treating peanut allergy in children and young people |
|
|
| Reslizumab |
|
Formulary
|
(Cinqaero®) concentrate for solution for infusion 25mg/2.5ml, 100mg/10ml Severe eosinophilic asthma as per NICE TA479 |
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
|
|
| Mepolizumab |
|
Formulary
|
Eosinophilic granulomatosis with polyangiitis in people 6 years and over. Appraisal terminated NICE TA845 |
|
| Mepolizumab |
|
Formulary
|
Severe chronic rhinosinusitis with nasal polyps in adults. Appraisal terminated. NICE TA847 |
|
|
Links
- NICE TA10: Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma
Asthma action plan child: Asthma UK- Asthma management plan: Asthma UK
- BNF: Antihistamines, allergen immunotherapy and allergic emergencies
- LSCMMG: Asthma Treatment Guideline for Adults
- LSCMMG: Asthma Treatment Guideline for Children
- LSCMMG: Chronic Obstructive Pulmonary Disease (COPD) Desktop Guideline
- MART asthma plan
- MHRA Drug Safety Update :Nebulised asthma rescue therapy in children: home use of nebulisers in paediatric asthma should be initiated and managed only by specialists
- MHRA: Omalizumab: potential risk of arterial thrombotic events
- MHRA: Omalizumab: potential risk of arterial thrombotic events
- MHRA: Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects
- NICE NG115: Chronic obstructive pulmonary disease in over 16s: diagnosis and management
- NICE NG209: Tobacco: preventing uptake, promoting quitting and treating dependence
- NICE NG80:Asthma: diagnosis, monitoring and chronic asthma management
- NICE TA278: Omalizumab for treating severe persistent allergic asthma
- NICE TA38: Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)
- NICE TA479: Reslizumab for treating severe eosinophilic asthma
- NICE TA565: Benralizumab for treating severe eosinophilic asthma
- NICE TA671: Mepolizumab for treating severe eosinophilic asthma
- NICE TA678: Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)
- NICE TA769: Palforzia for treating peanut allergy in children and young people
- NICE TA880 Tezepelumab for treating severe asthma